All stories by Sohini Das
India readies for massive testing exercise after lockdownRediff.com7 hours ago
The ICMR is working on a war footing to develop the testing ecosystem -- especially for the screening blood tests. NIV, Pune, is in the process of validating antibody-based screening kits.
PM's lockdown address best in terms of TV ratingsRediff.com8 hours ago
The telecast was viewed by 197 million Indians, higher than the Indian Premier League final which was watched by 133 million, reports Sohini Das.
COVID-19 test: Why patients opt out of private labsRediff.com1 days ago
At present, the cost of testing for COVID-19 is Rs 4,500 per examination and the results are available within 24 hours. Almost 90 per cent of queries fizzle out after patients realise the cost of testing will not be borne by the government.
Govt now allows doorstep delivery of drugsRediff.com1 days ago
Medicines that fall under Schedule H category (class of prescription drugs) would be provided against a valid prescription that can be submitted either physically or over e-mail. Narcotics, psychotropics and controlled substances, though, cannot be delivered.
Coronavirus impact: Govt restricts exports of 13 APIs, formulationsRediff.com4 Mar 2020
Exports of 13 APIs - including paracetamol, tinidazole, metronidazole, vitamin B1, vitamin B6, vitamin B12, acyclovir, progesterone - along with formulations made from these APIs, would be restricted.
Coronavirus outbreak: Domestic drug market stares at supply crisisRediff.com20 Feb 2020
Big pharma companies, however, said while it was true that formulation players would not rush to buy raw material, they could not afford losing customers.
Kohli is top celebrity brand for third time in a rowRediff.com17 Feb 2020
The Duff & Phelps report shows that Virat Kohli has increased his brand value by 40 per cent to $237.5 million in 2019 and taken a huge lead with his closest rival, Akshay Kumar, ranked second.
Coronavirus scare: India may soon run short of antibiotics, diabetes drugsRediff.com12 Feb 2020
Indian pharmaceutical companies are heavily dependent on China to source fermentation-based active pharmaceutical ingredients and intermediates to manufacture these medicines, but the coronavirus outbreak there has disrupted the supply.
Medical devices to be treated as drugs from next fiscalRediff.com12 Feb 2020
The new regime aims to bring in ease of doing business, as the NITI Aayog has proposed to do away with the need to have manufacturing licences to register medical devices or to get a certificate of compliance.
Coronavirus: Windfall likely for medical device firmsRediff.com7 Feb 2020
As fear grips the world, demand for protective gear used by health care professionals and citizens is on a rise. And, supply disruption from China has opened a window of opportunities for Indian medical device makers.
Price relief for diabetes patients as drugs go off patentRediff.com13 Jan 2020
At least two key drugs in the gliptin category have already gone off patent and cheaper variants are crowding the market. Also, several patent expiries are round the corner for the newest category of drugs - SGLT-2 inhibitors or gliflozins.
How Avengers stole the Indian box officeRediff.com1 Jan 2020
'If you look at the Number 1 film in India this year across Bollywood and other regional film industries, it is Avengers: Endgame.'
What is the future of e-pharmacies in India?Rediff.com19 Dec 2019
PharmEasy, 1mg and Netmeds believe that their disruptive capabilities will power their brands despite the recent court ruling. The Drug Controller General of India recently directed all state FDAs to stop the online sale of medicines as per a Delhi high court order of last year.
How govt plans to ensure faster availability of new drugsRediff.com16 Dec 2019
Concerned about the rise of antibiotic resistance and the time it takes for drugs developed abroad to reach Indians, the government is considering holding its own clinical trials. Clinical trials for new drugs have so far primarily been conducted only by private Indian or foreign drug firms. But given the stringent nature of India's regulatory environment for clinical trials, several pharmaceutical companies have moved their trials out of India. As a result, only 1.2 per cent of global clinical trials take place in India.
How govt plans to buy med devices cheaply for AyushmanRediff.com15 Dec 2019
According to a senior government official, the plan is to do "collective bargaining" for certain medical devices and implants by assuring a bulk requirement to the manufacturers. "The requirement for these devices runs into millions. We assure them that the requirement is going to be in bulk. In return, they should offer us better rates," he said.
Why prices of vitamin C, antibiotics could shoot upRediff.com14 Dec 2019
The government said that "in exercise of extraordinary powers in public interest, conferred by paragraph 19 of the DPCO, 2013", the ceiling prices of 21 key formulations had been increased. These formulations include common medicines like BCG vaccines, penicillin, malaria and leprosy medicines (Dapsone), life-saving drugs like Furosemide (used to treat fluid build-up due to heart failure, liver scarring, or kidney disease), vitamin C, some common antibiotics, and anti-allergy medicines.
Lupin sells Japan arm to Unison for Rs 3,702 crRediff.com12 Nov 2019
The company will now focus on specialty products in Japan; it is open to inorganic opportunities, especially in India.
Online ticket sales a bonanza for multiplexesRediff.com31 Oct 2019
Revenue from convenience fees has grown at a compound annual rate of 85 per cent for multiplex chain operator Inox Leisure and 58 per cent for PVR.
Drones will deliver critical drugs at your doorstepRediff.com17 Sep 2019
Maharashtra govt, California-based Zipline to launch the automated delivery service funded by Serum Institute.
Sun Pharma's Dilip Shanghvi takes 99% pay cutRediff.com2 Aug 2019
As on July 31, the valuation of his shareholding in the company stood at Rs 9,830 crore.
Despite cap on pricing import of medical devices risesRediff.com24 Jun 2019
The growth in imports was led by product categories such as diagnostic items, ultra-sonogram machines, MRI and ECG apparatus, syringes with needles, suture needles, digital thermometers, malaria diagnostic kits, and hearing aids.
2 reasons why drug sales are in poor healthRediff.com11 May 2019
Overall slowdown in the economy and growing volumes of unbranded generic medicines in the domestic market are behind poor sales.
How Saridon has managed to remain top of the mindRediff.com3 May 2019
What has worked though for Brand Saridon has been its single-minded focus on headaches as opposed to other analgesics that dwell on a wider set of problems, reports Sohini Das.
MNC pharma cos may be afflicted by pneumonia virusRediff.com22 Apr 2019
Aurobindo Pharma, Cadila Healthcare and Serum Institute are readying their vaccine candidates.
Why Jio may now have to buy spectrum from the open marketRediff.com20 Apr 2019
While the company insisted it had enough spectrum across circles, analysts said the company might soon need to acquire some spectrum to ensure uninterrupted service.
Raymond forays into real estate with Thane projectRediff.com4 Apr 2019
The project will house 3,000 residential units across 10 towers in the first phase on a 20-acre land parcel that Raymond owns in Thane
Why cold wave across US is good news for Indian drug cosRediff.com12 Mar 2019
Companies such as Cadila Healthcare, Lupin, and Natco, which sell generic versions of flu medication in the US market, are likely to benefit.
Jio likely to grab 51% revenue market share in 3 yearsRediff.com7 Jan 2019
Airtel and Vodafone Idea are also trying to expand the penetration of 4G users in their subscriber base as they take this network to the hinterland
As shares plunge to 5-year low, Sun Pharma promoters poorer by Rs 12,660 crore in 10 daysRediff.com6 Dec 2018
Sun Pharma's market capitalisation stood at Rs 100,050 crore on December 5, with its share price closing at Rs 417 a piece - lowest since March 2013.
Bhavdeep Singh, the CEO who championed organ donation quits FortisRediff.com9 Nov 2018
Singh, who was instrumental in building required capabilities in the organisation said his role at Fortis did not allow him to spend time with his family, as the reason behind his resignation.
J&J's loss may be good news for Indian pharmasRediff.com1 Nov 2018
Dr Reddy's, Glenmark, Wockhardt have lined up alternatives for Zytiga
Why drug firms' Q2 revenue growth is likely to dipRediff.com12 Oct 2018
Currency played an important role in Q2, with US dollar, Japanese yen and euro appreciating vis-a-vis the Indian rupee, while the Brazilian real, South African rand and Russian ruble depreciating against rupee.
Quality perceptions hobble Jan Aushadi drugsRediff.com10 Oct 2018
Large pharmaceutical firms feel that if the quality parameters and assurance levels are brought up to the level of branded generics, then Jan Aushadhi medicines would find it difficult to retain their affordability.
Why draft pharma policy may take time to see light of dayRediff.com25 Sep 2018
Some of the proposals (for example trade margin calculation for imported medical devices) were not approved by the PMO and were sent back for revisions.
How Amul is quelling the 'non-veg' rumoursRediff.com21 Sep 2018
This is not the first time Gujarat Cooperative Milk Marketing Federation that owns brand Amul has chosen an unconventional method to protect its brand.
Faulty hip implants: Centre to ask J&J to compensate victimsRediff.com30 Aug 2018
Once the patients are identified, the government will decide on the quantum of compensation in each case and then approach J&J for claim settlement.
How Manipal plans to spread its wings in IndiaRediff.com16 Aug 2018
Rough estimates show that at a rate of Rs 1 crore per hospital bed, the investment in India alone would be around Rs 2,000 crore
Pharma industry bounces back to good healthRediff.com12 Jun 2018
In May, price growth for drugs was in negative territory at (-)1 per cent
Why Modi's dream of starting bullet train by 2022 may be derailedRediff.com21 May 2018
While farmers in Gujarat are rejecting the compensation package, farmers in Maharashtra say they do not wish to part with their land for a project that largely benefits Gujarat.
Takeover battle over, Munjal-Burman team bags FortisRediff.com11 May 2018
Their offer values Fortis at over Rs 9,000 crore, or around Rs 172 per share.